Huntington's treatment hope after trial success

A new dopamine-regulating drug improves motor function and may slow disease progression in patients with Huntington's disease, a Phase III trial has shown.

A neurone from the striatum of the brain showing accumulation of huntingtin (fluorescent areas), the mutant protein that is responsible for Huntington's disease.
A neurone from the striatum of the brain showing accumulation of huntingtin (fluorescent areas), the mutant protein that is responsible for Huntington's disease.

Pridopidine (Huntexil) belongs to a class of medicines called dopaminergic stabilisers. These agents, typified by the antipsychotic aripiprazole (Abilify), counteract the effects of both excessive and insufficient dopaminergic activity.

Dopaminergic stabilisers have the potential to treat a wider range of Huntingdon's symptoms with a better tolerability profile than the currently licensed treatment, tetrabenazine (Xenazine 25). This drug promotes the degradation of dopamine, primarily relieving the hyperkinetic symptoms of the disease.

In the double-blind MermaiHD trial, investigators randomised a total of 437 patients to receive pridopidine 45mg once or twice daily, or placebo.

After 6 months, patients receiving pridopidine twice daily showed significant improvements in voluntary movements (p<0.02), global motor function (p<0.001) eye movements (p<0.002) and dystonia (p<0.001). They also exhibited a significant improvement in cognitive function (p<0.05).

The findings were comparable in patients taking and not taking antipsychotic medication. Pridopidine had a similar safety profile to that of placebo and did not appear to worsen cognitive or psychiatric symptoms.

Subsequent analysis of the MermaidHD results indicated that pridopidine might also have disease-modifying properties, in addition to its effect on symptoms. The drug was estimated to slow disease progression by up to 6–18 months.

NeuroSearch, the developer of pridopidine, expects to report data from a 12-month open-label extension of the MermaiHD trial in late 2010.

 

 


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases